These results indicate GATA2 as a potential independent prognostic marker in distinguishing PCa patients that may recur in the intermediate-risk cases who are the most difficult ones to avoid overtreatment when considering active surveillance or immediately determined therapy in clinic. This evidence concerns the gene GATA2 and posterior cortical atrophy.